The Company also announced that it has regained compliance with Nasdaq’s minimum bid price requirement, marking another positive development as Trinity Biotech continues to execute its strategic priorities.

Perceptive Advisors is one of the world's leading healthcare-focused investment firms, with a long track record of investing in and supporting innovative biotechnology, diagnostics and medical technology companies.

The latest investment builds on Perceptive Advisors’ longstanding support of Trinity Biotech, strengthening the Company’s liquidity and financial flexibility as it continues to execute its strategic priorities, including advancing its CGM+ continuous glucose monitoring platform, pursuing opportunities across its diagnostics and metabolic health businesses, and developing innovative liquid cooling solutions for AI data centre infrastructure through its Trinovium subsidiary.

The total investment of $7.0 million comprises approximately $2.5 million of new debt funding and approximately $4.5 million of capitalised interest under an amendment to the Company's existing financing arrangements.

Trinity Biotech also announced that on August 7, 2026, it received confirmation from The Nasdaq Stock Market LLC that the Company had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). For 10 consecutive business days, from July 24, 2026 through August 6, 2026, the closing bid price of the Company’s American Depositary Shares ("ADSs") was $1.00 per share or greater.